{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:09:23Z","timestamp":1790748563661,"version":"4.1.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40265-015-0416-8","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T19:23:19Z","timestamp":1433964199000},"page":"1071-1094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention"],"prefix":"10.1007","volume":"75","author":[{"given":"Ulrike","family":"Hostalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Gwilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"key":"416_CR1","unstructured":"International Diabetes Federation. Complications of diabetes. Available at: http:\/\/www.idf.org\/complications-diabetes . Accessed Jan 2015."},{"key":"416_CR2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/dc12-2625","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033\u201346.","journal-title":"Diabetes Care."},{"key":"416_CR3","unstructured":"World Health Organization. Diabetes: the cost of diabetes. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs236\/en\/ . Accessed Jan 2015."},{"issue":"Suppl 1","key":"416_CR4","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.2337\/dc15-S008","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142014. Diabetes Care. 2015;38(Suppl 1):S31\u20133.","journal-title":"Diabetes Care."},{"key":"416_CR5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/dom.12270","volume":"16","author":"C Merlotti","year":"2014","unstructured":"Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes: a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab. 2014;16:719\u201327.","journal-title":"Diabetes Obes Metab."},{"key":"416_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/diacare.15.3.318","volume":"15","author":"RA DeFronzo","year":"1992","unstructured":"DeFronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318\u201368.","journal-title":"Diabetes Care."},{"key":"416_CR7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0300-2977(97)00012-0","volume":"50","author":"RA DeFronzo","year":"1997","unstructured":"DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med. 1997;50:191\u20137.","journal-title":"Neth J Med."},{"key":"416_CR8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","volume":"30","author":"DM Nathan","year":"2007","unstructured":"Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753\u20139.","journal-title":"Diabetes Care."},{"key":"416_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.mcna.2010.11.002","volume":"95","author":"M Buysschaert","year":"2011","unstructured":"Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am. 2011;95:289\u201397.","journal-title":"Med Clin North Am"},{"key":"416_CR10","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035\u201387.","journal-title":"Eur Heart J."},{"key":"416_CR11","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.12.3331","volume":"26","author":"S Genuth","year":"2003","unstructured":"Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160\u20137.","journal-title":"Diabetes Care."},{"key":"416_CR12","unstructured":"World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999."},{"key":"416_CR13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.2337\/dc10-0752","volume":"33","author":"DM Mann","year":"2010","unstructured":"Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33:2190\u20135.","journal-title":"Diabetes Care"},{"key":"416_CR14","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1210\/jc.2010-2352","volume":"95","author":"RM Cohen","year":"2010","unstructured":"Cohen RM, Haggerty S, Herman H. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab. 2010;95:5203\u20136.","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 2","key":"416_CR15","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.2337\/dcS13-2011","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127\u201338.","journal-title":"Diabetes Care."},{"key":"416_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2337\/dc09-0341","volume":"33","author":"MK Rhee","year":"2010","unstructured":"Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KM, et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care. 2010;33:49\u201354.","journal-title":"Diabetes Care."},{"key":"416_CR17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc07-1796","volume":"31","author":"D Ziegler","year":"2008","unstructured":"Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA\/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464\u20139.","journal-title":"Diabetes Care."},{"key":"416_CR18","unstructured":"International Diabetes Federation Diabetes Atlas. 6th ed. Available at: http:\/\/www.idf.org\/diabetesatlas\/download-book . Accessed Jan 2015."},{"key":"416_CR19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","unstructured":"Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393\u2013403.","journal-title":"N Engl J Med."},{"key":"416_CR20","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/dc09-1150","volume":"33","author":"A Ramachandran","year":"2010","unstructured":"Ramachandran A, Arun N, Shetty AS, Snehalatha C. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). Diabetes Care. 2010;33:2164\u20138.","journal-title":"Diabetes Care."},{"key":"416_CR21","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.2337\/dc09-0440","volume":"32","author":"YJ Cheng","year":"2009","unstructured":"Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, et al. Association of A1c and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population: implication for diabetes diagnostic thresholds. Diabetes Care. 2009;32:2027\u201377.","journal-title":"Diabetes Care."},{"key":"416_CR22","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.2337\/dc07-0732","volume":"30","author":"TT Nguyen","year":"2007","unstructured":"Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in prediabetes and pre- hypertension: new findings and their research and clinical implications. Diabetes Care. 2007;30:2708\u201315.","journal-title":"Diabetes Care."},{"key":"416_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.106.685628","volume":"116","author":"EL Barr","year":"2007","unstructured":"Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151\u20137.","journal-title":"Circulation."},{"key":"416_CR24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233\u201340.","journal-title":"Diabetes Care."},{"key":"416_CR25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.161.3.397","volume":"161","author":"DECODE Study Group","year":"2001","unstructured":"DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397\u2013405.","journal-title":"Arch Intern Med."},{"key":"416_CR26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1463-1326.2007.00759.x","volume":"10","author":"M Tyrberg","year":"2008","unstructured":"Tyrberg M, Melander A, Lovestam-Adrian M, Lindblad U. Retinopathy in subjects with impaired fasting glucose: the NANSY-Eye baseline report. Diabetes Obes Metab. 2008;10:646\u201351.","journal-title":"Diabetes Obes Metab."},{"key":"416_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.2007.02043.x","volume":"24","author":"Diabetes Prevention Program Research Group","year":"2007","unstructured":"Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137\u201344.","journal-title":"Diabet Med."},{"issue":"3 Suppl","key":"416_CR28","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1016\/j.amjcard.2011.03.013","volume":"108","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108(3 Suppl):3B\u201324B.","journal-title":"Am J Cardiol"},{"key":"416_CR29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1479164112451581","volume":"9","author":"L Ryd\u00e9n","year":"2012","unstructured":"Ryd\u00e9n L, Mellbin L. Glucose perturbations and cardiovascular risk: challenges and opportunities. Diabetes Vasc Dis Res. 2012;9:170\u20136.","journal-title":"Diabetes Vasc Dis Res."},{"key":"416_CR30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.mcna.2010.11.005","volume":"95","author":"E Ferrannini","year":"2011","unstructured":"Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am. 2011;95:327\u201339.","journal-title":"Med Clin North Am"},{"key":"416_CR31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","volume":"18","author":"I Hopper","year":"2011","unstructured":"Hopper I, Billah B, Skiba M, Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 2011;18:813\u201323.","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"416_CR32","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.ajem.2012.03.004","volume":"30","author":"R Bingisser","year":"2012","unstructured":"Bingisser R, Cairns C, Christ M, Hausfater P, Lindahl B, Mair J, et al. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med. 2012;30:1639\u201349.","journal-title":"Am J Emerg Med."},{"key":"416_CR33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.114.010815","volume":"130","author":"E Selvin","year":"2014","unstructured":"Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130:1374\u201382.","journal-title":"Circulation."},{"issue":"Suppl 1","key":"416_CR34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1055\/s-0029-1240928","volume":"42","author":"B Paulweber","year":"2010","unstructured":"Paulweber B, Valensi P, Lindstr\u00f6m J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42(Suppl 1):S3\u201336.","journal-title":"Horm Metab Res."},{"key":"416_CR35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","volume":"49","author":"A Natali","year":"2006","unstructured":"Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006;49:434\u201341.","journal-title":"Diabetologia"},{"key":"416_CR36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/0026-0495(93)90284-U","volume":"42","author":"AB Johnson","year":"1993","unstructured":"Johnson AB, Webster JM, Sum CF, Argyraki M, Cooper BG, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1993;42:1217\u201322.","journal-title":"Metabolism."},{"key":"416_CR37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jdiacomp.2005.08.010","volume":"20","author":"AD Wright","year":"2006","unstructured":"Wright AD, Cull CA, Macleod KM, Holman RR. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complicat. 2006;20:395\u2013401.","journal-title":"J Diabetes Complicat."},{"key":"416_CR38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1476-5381.1994.tb13128.x","volume":"112","author":"CJ Bailey","year":"1994","unstructured":"Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol. 1994;112:671\u20135.","journal-title":"Br J Pharmacol."},{"key":"416_CR39","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.1992.tb09093.x","volume":"105","author":"CJ Bailey","year":"1992","unstructured":"Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105:1009\u201313.","journal-title":"Br J Pharmacol."},{"key":"416_CR40","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.diabres.2014.08.004","volume":"106","author":"T Wu","year":"2014","unstructured":"Wu T, Thazhath SS, Bound MJ, Jones KL, Horowitz M, Rayner CK. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract. 2014;106:e3\u20136.","journal-title":"Diabetes Res Clin Pract"},{"key":"416_CR41","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/j.1464-5491.2012.03675.x","volume":"29","author":"SK Thondam","year":"2012","unstructured":"Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus. Diabet Med. 2012;29:e205\u201310.","journal-title":"Diabet Med"},{"key":"416_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.metabol.2010.01.001","volume":"60","author":"J Cuthbertson","year":"2011","unstructured":"Cuthbertson J, Patterson S, O\u2019Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2011;60:52\u20136.","journal-title":"Metabolism."},{"key":"416_CR43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/dom.12128","volume":"16","author":"Y Liu","year":"2014","unstructured":"Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab. 2014;16:111\u20137.","journal-title":"Diabetes Obes Metab."},{"key":"416_CR44","doi-asserted-by":"crossref","first-page":"e100778","DOI":"10.1371\/journal.pone.0100778","volume":"9","author":"A Napolitano","year":"2014","unstructured":"Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e100778.","journal-title":"PLoS One."},{"key":"416_CR45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122:253\u201370.","journal-title":"Clin Sci (Lond)"},{"key":"416_CR46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","volume":"494","author":"RA Miller","year":"2013","unstructured":"Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256\u201360.","journal-title":"Nature."},{"key":"416_CR47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/diacare.24.3.489","volume":"24","author":"E Mannucci","year":"2001","unstructured":"Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24:489\u201394.","journal-title":"Diabetes Care."},{"key":"416_CR48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2006.07.043","volume":"547","author":"BD Green","year":"2006","unstructured":"Green BD, Irwin N, Duffy NA, Gault VA, O\u2019harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006;547:192\u20139.","journal-title":"Eur J Pharmacol."},{"key":"416_CR49","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.102.034140","volume":"302","author":"DS Wang","year":"2002","unstructured":"Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510\u20135.","journal-title":"J Pharmacol Exp Ther."},{"key":"416_CR50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/FPC.0b013e328333bb11","volume":"20","author":"ML Becker","year":"2010","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010;20:38\u201344.","journal-title":"Pharmacogenet Genomics."},{"key":"416_CR51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet. 1998;352:854\u201365.","journal-title":"Lancet."},{"key":"416_CR52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med."},{"key":"416_CR53","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"A Kooy","year":"2009","unstructured":"Kooy A, de Jager J, Lehert P, Bets D, Wulffel\u00e9 MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616\u201325.","journal-title":"Arch Intern Med."},{"key":"416_CR54","unstructured":"University of Oxford Diabetes Trials Unit. Glucose lowering in non-diabetic hyperglycaemia trial (ongoing). Available at: https:\/\/www.dtu.ox.ac.uk\/GLINT\/ . Accessed Jan 2015."},{"key":"416_CR55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/joim.12128","volume":"275","author":"J Jager de","year":"2014","unstructured":"de Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275:59\u201370.","journal-title":"J Intern Med."},{"key":"416_CR56","unstructured":"Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P, editors. Metformin, the gold standard: a scientific handbook. Chichester: Wiley, 2007. p. 135\u2013152."},{"key":"416_CR57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/14746514010010010501","volume":"1","author":"JHB Scarpello","year":"2001","unstructured":"Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis. 2001;1:28\u201336.","journal-title":"Br J Diabetes Vasc Dis."},{"key":"416_CR58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/14746514070070050501","volume":"7","author":"MD Feher","year":"2007","unstructured":"Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage) in individuals intolerant to standard metformin: results from four UK centres. Br J Diabetes Vasc Dis. 2007;7:225\u20138.","journal-title":"Br J Diabetes Vasc Dis."},{"key":"416_CR59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.28.3.539","volume":"28","author":"DR Cryer","year":"2005","unstructured":"Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach. The COSMIC Approach Study. Diabetes Care. 2005;28:539\u201343.","journal-title":"Diabetes Care."},{"key":"416_CR60","unstructured":"Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P, editors. Metformin, the gold standard: a scientific handbook. Chichester: Wiley; 2007. p. 173\u2013192."},{"key":"416_CR61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/0022-3859.123143","volume":"59","author":"AK Singh","year":"2013","unstructured":"Singh AK, Kumar A, Karmakar D, Jha RK. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med. 2013;59:253\u20137.","journal-title":"J Postgrad Med."},{"key":"416_CR62","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","volume":"340","author":"J Jager de","year":"2010","unstructured":"de Jager J, Kooy A, Lehert P, Wulffel\u00e9 MG, van der Kolk J, Bets D, et al. Long-term treatment with metformin in patients with type 2 diabetes treated with insulin and risk of vitamin B12 deficiency: a randomised, placebo-controlled trial. BMJ. 2010;340:c2181.","journal-title":"BMJ."},{"key":"416_CR63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11739-014-1157-5","volume":"10","author":"M Niafar","year":"2015","unstructured":"Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10:93\u2013102.","journal-title":"Intern Emerg Med."},{"key":"416_CR64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(10)60746-5","volume":"376","author":"B Zinman","year":"2010","unstructured":"Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376:103\u201311.","journal-title":"Lancet."},{"key":"416_CR65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","volume":"49","author":"A Ramachandran","year":"2006","unstructured":"Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289\u201397.","journal-title":"Diabetologia."},{"key":"416_CR66","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1464-5491.1999.00090.x","volume":"16","author":"CL Li","year":"1999","unstructured":"Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16:477\u201381.","journal-title":"Diabet Med."},{"key":"416_CR67","doi-asserted-by":"crossref","first-page":"867604","DOI":"10.1155\/2012\/867604","volume":"2012","author":"MZ Iqbal Hydrie","year":"2012","unstructured":"Iqbal Hydrie MZ, Basit A, Shera AS, Hussain A. Effect of intervention in subjects with high risk of diabetes mellitus in Pakistan. J Nutr Metab. 2012;2012:867604.","journal-title":"J Nutr Metab."},{"key":"416_CR68","first-page":"131","volume":"17","author":"Y Wenying","year":"2001","unstructured":"Wenying Y, Lixiang L, Jinwu Q, Guangwei L, Zhiqing Y, Xiaoren P. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab. 2001;17:131\u20134.","journal-title":"Chin J Endocrinol Metab."},{"key":"416_CR69","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","volume":"374","author":"WC Knowler","year":"2009","unstructured":"Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677\u201386.","journal-title":"Lancet."},{"key":"416_CR70","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, H\u00e4m\u00e4l\u00e4inen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343\u201350.","journal-title":"N Engl J Med."},{"key":"416_CR71","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","volume":"20","author":"XR Pan","year":"1997","unstructured":"Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537\u201344.","journal-title":"Diabetes Care."},{"key":"416_CR72","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"JL Chiasson","year":"2002","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072\u20137.","journal-title":"Lancet."},{"key":"416_CR73","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"JL Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u201394.","journal-title":"JAMA."},{"key":"416_CR74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6strom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care."},{"key":"416_CR75","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69829-2","volume":"368","author":"HC Gerstein","year":"2006","unstructured":"Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096\u2013105.","journal-title":"Lancet."},{"key":"416_CR76","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","volume":"355","author":"DREAM Trial Investigators","year":"2006","unstructured":"DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551\u201362.","journal-title":"N Engl J Med."},{"key":"416_CR77","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00125-009-1315-x","volume":"52","author":"A Ramachandran","year":"2009","unstructured":"Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, et al. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia. 2009;52:1019\u201326.","journal-title":"Diabetologia."},{"key":"416_CR78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1112082","volume":"367","author":"LM Carlsson","year":"2012","unstructured":"Carlsson LM, Peltonen M, Ahlin S, Anveden \u00c5, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695\u2013704.","journal-title":"N Engl J Med."},{"key":"416_CR79","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/diacare.22.4.623","volume":"22","author":"Diabetes Prevention Program Research Group","year":"1999","unstructured":"Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623\u201334.","journal-title":"Diabetes Care."},{"issue":"Suppl 2","key":"416_CR80","first-page":"B11","volume":"23","author":"WY Fujimoto","year":"2000","unstructured":"Fujimoto WY. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care. 2000;23(Suppl 2):B11\u20133.","journal-title":"Diabetes Care."},{"key":"416_CR81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7326\/0003-4819-142-5-200503010-00007","volume":"142","author":"WH Herman","year":"2005","unstructured":"Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323\u201332.","journal-title":"Ann Intern Med."},{"key":"416_CR82","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2337\/dc09-0523","volume":"32","author":"L Perreault","year":"2009","unstructured":"Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009;32:1583\u20138.","journal-title":"Diabetes Care."},{"key":"416_CR83","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/diacare.26.4.977","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","unstructured":"Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003;26:977\u201380.","journal-title":"Diabetes Care."},{"key":"416_CR84","unstructured":"Diabetes Prevention Program Outcomes Study (DPPOS). Clinicaltrials.gov identifier NCT00038727. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00038727 . Accessed Jan 2015."},{"key":"416_CR85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/db14-0333","volume":"64","author":"RF Hamman","year":"2015","unstructured":"Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi C, Crandall J, et al. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcome Study (DPPOS). Diabetes. 2015;64:989\u201398.","journal-title":"Diabetes."},{"key":"416_CR86","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(12)60525-X","volume":"379","author":"L Perreault","year":"2012","unstructured":"Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243\u201351.","journal-title":"Lancet."},{"key":"416_CR87","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2337\/dc10-1033","volume":"33","author":"RR Rubin","year":"2010","unstructured":"Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2010;33:2549\u201351.","journal-title":"Diabetes Care."},{"key":"416_CR88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1464-5491.2012.03750.x","volume":"30","author":"TJ Orchard","year":"2013","unstructured":"Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46\u201355.","journal-title":"Diabet Med."},{"key":"416_CR89","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"Diabetes Prevention Program Research Group","year":"2012","unstructured":"Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35:731\u20137.","journal-title":"Diabetes Care."},{"key":"416_CR90","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/db06-0918","volume":"56","author":"JM Lachin","year":"2007","unstructured":"Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007;56:1153\u20139.","journal-title":"Diabetes."},{"key":"416_CR91","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","volume":"54","author":"AE Kitabchi","year":"2005","unstructured":"Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404\u201314.","journal-title":"Diabetes."},{"key":"416_CR92","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/db07-0009","volume":"56","author":"WY Fujimoto","year":"2007","unstructured":"Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56:1680\u20135.","journal-title":"Diabetes."},{"key":"416_CR93","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/oby.2006.246","volume":"14","author":"Diabetes Prevention Program Research Group","year":"2006","unstructured":"Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring). 2006;14:2107\u201317.","journal-title":"Obesity (Silver Spring)."},{"key":"416_CR94","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ajcn\/87.5.1212","volume":"87","author":"GA Bray","year":"2008","unstructured":"Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr. 2008;87:1212\u20138.","journal-title":"Am J Clin Nutr."},{"key":"416_CR95","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/oby.2008.224","volume":"16","author":"DS West","year":"2008","unstructured":"West DS, Elaine Prewitt T, Bursac Z, Felix HC. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring). 2008;16:1413\u201320.","journal-title":"Obesity (Silver Spring)"},{"key":"416_CR96","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc07-2390","volume":"31","author":"L Perreault","year":"2008","unstructured":"Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care. 2008;31:1416\u201321.","journal-title":"Diabetes Care."},{"key":"416_CR97","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2337\/dc06-0454","volume":"29","author":"EA Walker","year":"2006","unstructured":"Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006;29:1997\u20132002.","journal-title":"Diabetes Care."},{"key":"416_CR98","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1210\/jc.2008-0772","volume":"93","author":"RE Ratner","year":"2008","unstructured":"Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93:4774\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"416_CR99","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s11606-012-2122-5","volume":"27","author":"H Florez","year":"2012","unstructured":"Florez H, Pan Q, Ackermann RT, Marrero DG, Barrett-Connor E, Delahanty L, et al. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012;27:1594\u2013601.","journal-title":"J Gen Intern Med."},{"key":"416_CR100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11136-013-0436-3","volume":"23","author":"D Marrero","year":"2014","unstructured":"Marrero D, Pan Q, Barrett-Connor E, de Groot M, Zhang P, Percy C, et al. Impact of diagnosis of diabetes on health-related quality of life among high risk individuals: the Diabetes Prevention Program outcomes study. Qual Life Res. 2014;23:75\u201388.","journal-title":"Qual Life Res."},{"key":"416_CR101","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/db07-1419","volume":"57","author":"KJ Mather","year":"2008","unstructured":"Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008;57:980\u20136.","journal-title":"Diabetes."},{"key":"416_CR102","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2337\/diacare.28.4.830","volume":"28","author":"RR Rubin","year":"2005","unstructured":"Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, et al. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care. 2005;28:830\u20137.","journal-title":"Diabetes Care."},{"key":"416_CR103","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc07-1827","volume":"31","author":"RR Rubin","year":"2008","unstructured":"Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31:420\u20136.","journal-title":"Diabetes Care."},{"key":"416_CR104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3945\/ajcn.2008.27382","volume":"90","author":"JP Crandall","year":"2009","unstructured":"Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, et al. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am J Clin Nutr. 2009;90:595\u2013601.","journal-title":"Am J Clin Nutr."},{"key":"416_CR105","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","volume":"28","author":"R Ratner","year":"2005","unstructured":"Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888\u201394.","journal-title":"Diabetes Care"},{"key":"416_CR106","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","volume":"142","author":"TJ Orchard","year":"2005","unstructured":"Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611\u20139.","journal-title":"Ann Intern Med."},{"key":"416_CR107","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc08-0494","volume":"32","author":"RB Goldberg","year":"2009","unstructured":"Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32:726\u201332.","journal-title":"Diabetes Care."},{"key":"416_CR108","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2337\/dc08-1400","volume":"32","author":"Diabetes Prevention Program Research Group","year":"2009","unstructured":"Diabetes Prevention Program Research Group. Changes in albumin excretion in the diabetes prevention program. Diabetes Care. 2009;32:720\u20135.","journal-title":"Diabetes Care."},{"key":"416_CR109","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc08-0148","volume":"31","author":"AN Friedman","year":"2008","unstructured":"Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan KM, Barrett-Connor E, et al. Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care. 2008;31:2344\u20138.","journal-title":"Diabetes Care."},{"key":"416_CR110","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/oby.2010.21","volume":"18","author":"J Krakoff","year":"2010","unstructured":"Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring). 2010;18:1762\u20137.","journal-title":"Obesity (Silver Spring)."},{"key":"416_CR111","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","volume":"54","author":"S Haffner","year":"2005","unstructured":"Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566\u201372.","journal-title":"Diabetes"},{"key":"416_CR112","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.pgen.1002895","volume":"8","author":"TI Pollin","year":"2012","unstructured":"Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, et al. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet. 2012;8:e1002895.","journal-title":"PLoS Genet."},{"key":"416_CR113","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db10-1119","volume":"60","author":"MF Hivert","year":"2011","unstructured":"Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011;60:1340\u20138.","journal-title":"Diabetes."},{"key":"416_CR114","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2337\/db10-0543","volume":"59","author":"KA Jablonski","year":"2010","unstructured":"Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59:2672\u201381.","journal-title":"Diabetes."},{"key":"416_CR115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2337\/dc11-1328","volume":"35","author":"LM Delahanty","year":"2012","unstructured":"Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care. 2012;35:363\u20136.","journal-title":"Diabetes Care."},{"key":"416_CR116","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00125-007-0891-x","volume":"51","author":"JC Florez","year":"2008","unstructured":"Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, et al. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia. 2008;51:451\u20137.","journal-title":"Diabetologia."},{"key":"416_CR117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa062418","volume":"355","author":"JC Florez","year":"2006","unstructured":"Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241\u201350.","journal-title":"N Engl J Med."},{"key":"416_CR118","doi-asserted-by":"crossref","first-page":"e44424","DOI":"10.1371\/journal.pone.0044424","volume":"7","author":"JC Florez","year":"2012","unstructured":"Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, et al. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One. 2012;7:e44424.","journal-title":"PLoS One."},{"key":"416_CR119","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2337\/dc11-2301","volume":"35","author":"JC Florez","year":"2012","unstructured":"Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, et al. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care. 2012;35:1864\u20137.","journal-title":"Diabetes Care."},{"key":"416_CR120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3132\/dvdr.2008.005","volume":"5","author":"C Snehalatha","year":"2008","unstructured":"Snehalatha C, Mary S, Joshi VV, Ramachandran A. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res. 2008;5:25\u20139.","journal-title":"Diab Vasc Dis Res."},{"key":"416_CR121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1464-5491.2011.03392.x","volume":"29","author":"A Ramachandran","year":"2012","unstructured":"Ramachandran A, Snehalatha C, Samith Shetty A, Nanditha A. Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance: analysis of the Indian Diabetes Prevention Programmes. Diabet Med. 2012;29:94\u20138.","journal-title":"Diabet Med."},{"key":"416_CR122","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2337\/dc09-0676","volume":"32","author":"C Snehalatha","year":"2009","unstructured":"Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SB, Nanditha A, et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care. 2009;32:1796\u2013801.","journal-title":"Diabetes Care."},{"key":"416_CR123","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diabres.2006.08.009","volume":"76","author":"A Ramachandran","year":"2007","unstructured":"Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians: result of Indian Diabetes Prevention Programme. Diabetes Res Clin Pract. 2007;76:215\u20138.","journal-title":"Diabetes Res Clin Pract."},{"key":"416_CR124","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2337\/dc11-0046","volume":"34","author":"R Retnakaran","year":"2011","unstructured":"Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care. 2011;34:1601\u20134.","journal-title":"Diabetes Care."},{"key":"416_CR125","unstructured":"European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/09\/news_detail_001119.jsp . Accessed Jan 2015."},{"key":"416_CR126","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4158\/EP11194.OR","volume":"18","author":"J Armato","year":"2012","unstructured":"Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and \u03b2-cell dysfunction. Endocr Pract. 2012;18:342\u201350.","journal-title":"Endocr Pract."},{"key":"416_CR127","first-page":"363","volume":"55","author":"M Lily","year":"2009","unstructured":"Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009;55:363\u20139.","journal-title":"Can Fam Physician."},{"key":"416_CR128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1753-6405.2010.00503.x","volume":"34","author":"A Yuen","year":"2010","unstructured":"Yuen A, Sugeng Y, Weiland TJ, Jelinek GA. Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Aust N Z J Public Health. 2010;34:172\u20138.","journal-title":"Aust N Z J Public Health"},{"key":"416_CR129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0028-1087177","volume":"117","author":"EA Andreadis","year":"2009","unstructured":"Andreadis EA, Katsanou PM, Georgiopoulos DX, Tsourous GI, Yfanti GK, Gouveri ET, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects\u2013the Carmos study. Exp Clin Endocrinol Diabetes. 2009;117:175\u201380.","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"416_CR130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/dc11-0925","volume":"35","author":"SK Malin","year":"2012","unstructured":"Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care. 2012;35:131\u20136.","journal-title":"Diabetes Care."},{"issue":"Suppl 6","key":"416_CR131","first-page":"S131","volume":"93","author":"N Numbenjapon","year":"2010","unstructured":"Numbenjapon N, Nakavachara P, Santiprabhob J, Kiattisakthavee P, Wongarn R, Likitmaskul S. Successful strategy to improve glucose tolerance in Thai obese youth. J Med Assoc Thai. 2010;93(Suppl 6):S131\u20138.","journal-title":"J Med Assoc Thai."},{"key":"416_CR132","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2009.03.005","volume":"35","author":"A Fontbonne","year":"2009","unstructured":"Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper\u2013body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab. 2009;35:385\u201391.","journal-title":"Diabetes Metab."},{"key":"416_CR133","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1464-5491.2001.00539.x","volume":"18","author":"M Lehtovirta","year":"2001","unstructured":"Lehtovirta M, Fors\u00e9n B, Gullstr\u00f6m M, H\u00e4ggblom M, Eriksson JG, Taskinen MR, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18:578\u201383.","journal-title":"Diabet Med."},{"key":"416_CR134","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/1471-2458-10-575","volume":"10","author":"SP Garnett","year":"2010","unstructured":"Garnett SP, Baur LA, Noakes M, Steinbeck K, Woodhead HJ, Burrell S, et al. Researching Effective Strategies to Improve Insulin Sensitivity in Children and Teenagers\u2014RESIST. A randomised control trial investigating the effects of two different diets on insulin sensitivity in young people with insulin resistance and\/or pre-diabetes. BMC Public Health. 2010;10:575.","journal-title":"BMC Public Health."},{"key":"416_CR135","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2006-0241","volume":"91","author":"S Srinivasan","year":"2006","unstructured":"Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074\u201380.","journal-title":"J Clin Endocrinol Metab."},{"key":"416_CR136","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1542\/peds.107.4.e55","volume":"107","author":"M Freemark","year":"2001","unstructured":"Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.","journal-title":"Pediatrics."},{"key":"416_CR137","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/meta.2001.28078","volume":"50","author":"JP Kay","year":"2001","unstructured":"Kay JP, Alemzadeh R, Langley G, D\u2019Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457\u201361.","journal-title":"Metabolism."},{"key":"416_CR138","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/jc.2012-2710","volume":"98","author":"D Kendall","year":"2013","unstructured":"Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013;98:322\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"416_CR139","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.metabol.2012.02.003","volume":"61","author":"RA G\u00f3mez-D\u00edaz","year":"2012","unstructured":"G\u00f3mez-D\u00edaz RA, Talavera JO, Pool EC, Ortiz-Navarrete FV, Sol\u00f3rzano-Santos F, Mondrag\u00f3n-Gonz\u00e1lez R, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. Metabolism. 2012;61:1247\u201355.","journal-title":"Metabolism."},{"key":"416_CR140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijo.0803453","volume":"31","author":"JF Fu","year":"2007","unstructured":"Fu JF, Liang L, Zou CC, Hong F, Wang CL, Wang XM, et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes (Lond). 2007;31:15\u201322.","journal-title":"Int J Obes (Lond)."},{"key":"416_CR141","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1467-789X.2009.00697.x","volume":"11","author":"SM Quinn","year":"2010","unstructured":"Quinn SM, Baur LA, Garnett SP, Cowell CT. Treatment of clinical insulin resistance in children: a systematic review. Obes Rev. 2010;11:722\u201330.","journal-title":"Obes Rev."},{"key":"416_CR142","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4088\/JCP.10m06822","volume":"73","author":"P Manu","year":"2012","unstructured":"Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73:460\u20136.","journal-title":"J Clin Psychiatry."},{"key":"416_CR143","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","volume":"169","author":"RR Wu","year":"2012","unstructured":"Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo\u2013controlled study. Am J Psychiatry. 2012;169:813\u201321.","journal-title":"Am J Psychiatry."},{"key":"416_CR144","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","volume":"138","author":"M Wang","year":"2012","unstructured":"Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012;138:54\u20137.","journal-title":"Schizophr Res."},{"key":"416_CR145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4088\/JCP.09m05580","volume":"73","author":"VP Hoffmann","year":"2012","unstructured":"Hoffmann VP, Case M, Jacobson JG. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry. 2012;73:216\u201323.","journal-title":"J Clin Psychiatry."},{"key":"416_CR146","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","volume":"113","author":"E Carrizo","year":"2009","unstructured":"Carrizo E, Fern\u00e1ndez V, Connell L, Sandia I, Prieto D, Mogoll\u00f3n J, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double\u2013blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113:19\u201326.","journal-title":"Schizophr Res."},{"key":"416_CR147","first-page":"185","volume":"299","author":"RR Wu","year":"2008","unstructured":"Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299:185\u201393.","journal-title":"JAMA."},{"key":"416_CR148","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.pnpbp.2007.11.013","volume":"32","author":"CH Chen","year":"2008","unstructured":"Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:925\u201331.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"416_CR149","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/appi.ajp.163.12.2072","volume":"163","author":"DJ Klein","year":"2006","unstructured":"Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163:2072\u20139.","journal-title":"Am J Psychiatry."},{"key":"416_CR150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","volume":"93","author":"T Baptista","year":"2007","unstructured":"Baptista T, Rangel N, Fern\u00e1ndez V, Carrizo E, El Fakih Y, Uzc\u00e1tegui E, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo\u2013controlled trial. Schizophr Res. 2007;93:99\u2013108.","journal-title":"Schizophr Res."},{"key":"416_CR151","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2125.2010.03783.x","volume":"71","author":"SK Praharaj","year":"2011","unstructured":"Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377\u201382.","journal-title":"Br J Clin Pharmacol."},{"key":"416_CR152","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.09m05274yel","volume":"71","author":"M Ehret","year":"2010","unstructured":"Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010;71:1286\u201392.","journal-title":"J Clin Psychiatry."},{"key":"416_CR153","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/0269881109353461","volume":"25","author":"L Bj\u00f6rkhem-Bergman","year":"2011","unstructured":"Bj\u00f6rkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25:299\u2013305.","journal-title":"J Psychopharmacol."},{"key":"416_CR154","first-page":"1130","volume":"29","author":"S Arman","year":"2008","unstructured":"Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29:1130\u20134.","journal-title":"Saudi Med J."},{"key":"416_CR155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/070674370605100310","volume":"51","author":"T Baptista","year":"2006","unstructured":"Baptista T, Mart\u00ednez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006;51:192\u20136.","journal-title":"Can J Psychiatry."},{"key":"416_CR156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0b013e32801182e6","volume":"22","author":"T Baptista","year":"2007","unstructured":"Baptista T, Sandia I, Lacruz A, Rangel N, de Mendoza S, Beaulieu S, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol. 2007;22:69\u201376.","journal-title":"Int Clin Psychopharmacol."},{"key":"416_CR157","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diacare.26.1.36","volume":"26","author":"WH Hernan","year":"2003","unstructured":"Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26:36\u201347.","journal-title":"Diabetes Care."},{"key":"416_CR158","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.2337\/diacare.26.9.2518","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","unstructured":"Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518\u201323.","journal-title":"Diabetes Care."},{"key":"416_CR159","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2337\/dc11-1468","volume":"35","author":"Diabetes Prevention Program Research Group","year":"2012","unstructured":"Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP\/DPPOS. Diabetes Care. 2012;35:723\u201330.","journal-title":"Diabetes Care."},{"key":"416_CR160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-143-4-200508160-00006","volume":"143","author":"DM Eddy","year":"2005","unstructured":"Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251\u201364.","journal-title":"Ann Intern Med."},{"key":"416_CR161","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0149-2918(04)90029-X","volume":"26","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304\u201321.","journal-title":"Clin Ther."},{"key":"416_CR162","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pcd.2011.10.006","volume":"6","author":"AJ Palmer","year":"2012","unstructured":"Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012;6:109\u201321.","journal-title":"Prim Care Diabetes."},{"key":"416_CR163","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1464-5491.2007.02108.x","volume":"24","author":"A Icks","year":"2007","unstructured":"Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, et al. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a \u2018real world\u2019 routine healthcare setting: model based on the KORA Survey 2000. Diabet Med. 2007;24:473\u201380.","journal-title":"Diabet Med."},{"key":"416_CR164","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.2337\/dc07-0150","volume":"30","author":"A Ramachandran","year":"2007","unstructured":"Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30:2548\u201352.","journal-title":"Diabetes Care."},{"key":"416_CR165","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00125-010-1661-8","volume":"53","author":"MY Bertram","year":"2010","unstructured":"Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53:875\u201381.","journal-title":"Diabetologia."},{"key":"416_CR166","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2458-12-16","volume":"12","author":"ME Passey","year":"2012","unstructured":"Passey ME, Shrestha RN, Bertram MY, Schofield DJ, Vos T, Callander EJ, et al. The impact of diabetes prevention on labour force participation and income of older Australians: an economic study. BMC Public Health. 2012;12:16.","journal-title":"BMC Public Health."},{"key":"416_CR167","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11532880-000000000-00000","volume":"8","author":"TM Schaufler","year":"2010","unstructured":"Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8:191\u2013202.","journal-title":"Appl Health Econ Health Policy."},{"key":"416_CR168","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1464-5491.2004.01330.x","volume":"21","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Getsios D, Caro I, Klittich WS, O\u2019Brien JA. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med. 2004;21:1229\u201336.","journal-title":"Diabet Med."},{"key":"416_CR169","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2337\/dc10-0054","volume":"33","author":"R Chatterjee","year":"2010","unstructured":"Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care. 2010;33:1484\u201390.","journal-title":"Diabetes Care."},{"key":"416_CR170","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc12-1752","volume":"36","author":"R Chatterjee","year":"2013","unstructured":"Chatterjee R, Narayan KM, Lipscomb J, Jackson SL, Long Q, Zhu M, et al. Screening for diabetes and prediabetes should be cost-saving in patients at high risk. Diabetes Care. 2013;36:1981\u20137.","journal-title":"Diabetes Care."},{"key":"416_CR171","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5694\/j.1326-5377.2007.tb00998.x","volume":"186","author":"SM Twigg","year":"2007","unstructured":"Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461\u20135.","journal-title":"Med J Aust."},{"key":"416_CR172","unstructured":"Guzman JR. Documentos Selectos de Posici\u00f3n y Consenso de ALAD (Associati\u00f3n Lationoamericano de diabetes) Ac Farmac\u00e9utica; 2011. ISBN: 9788560549559."},{"key":"416_CR173","first-page":"S16","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","unstructured":"Committee Canadian Diabetes Association Clinical Practice Guidelines Expert. Reducing the risk of developing diabetes. Can J Diabetes. 2013;37:S16\u20139.","journal-title":"Can J Diabetes."},{"key":"416_CR174","unstructured":"Ministerio de Salud. Gobierno de Chile. Gu\u00eda Cl\u00ednica Diabetes Mellitas Tipo 2. Serie Gu\u00edas C\u00ednicas Minsal 2010. Available at: http:\/\/web.minsal.cl\/portal\/url\/item\/72213ed52c3e23d1e04001011f011398.pdf . Accessed Jan 2015."},{"key":"416_CR175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-5491.2007.02157.x","volume":"24","author":"KG Alberti","year":"2007","unstructured":"Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451\u201363.","journal-title":"Diabet Med."},{"key":"416_CR176","unstructured":"Instituto Mexicano del Seguro Social. Gu\u00eda de Practica Clinica (GPC). Diagn\u00f3stico y Tratamiento de la Diabetes Mellitas tipo 2. Evidencias y Recomendaciones 2009 [extract]. Available at: http:\/\/www.imss.gob.mx\/sites\/all\/statics\/guiasclinicas\/000GER_DiabetesMellitus.pdf . Accessed Jan 2015."},{"key":"416_CR177","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2008-0222","volume":"93","author":"JL Rosenzweig","year":"2008","unstructured":"Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3671\u201389.","journal-title":"J Clin Endocrinol Metab."},{"key":"416_CR178","unstructured":"Malaysian Endocrine Metabolic Society. Management of type 2 diabetes mellitus. 4th ed. 2009. Available at: http:\/\/www.moh.gov.my\/attachments\/3878.pdf . Accessed Jan 2015."},{"key":"416_CR179","unstructured":"Ministrio de Sanidad y Consumo. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre diabetes tipo 2. Gu\u00edasa Pr\u00e1ctica Cl\u00ednica en el SNS 2008. Available at: http:\/\/www.guiasalud.es\/GPC\/GPC_429_Diabetes_2_Osteba_compl.pdf . Accessed Jan 2015."},{"issue":"Suppl 1","key":"416_CR180","first-page":"1","volume":"10","author":"Gu\u00eda Cl\u00ednica Pr\u00e1ctica en Diabetes Mellitus","year":"2012","unstructured":"Gu\u00eda Cl\u00ednica Pr\u00e1ctica en Diabetes Mellitus. Revista Venezolana de Endocrinologia y Metabolismo. 2012;10(Suppl 1):1\u2013155.","journal-title":"Revista Venezolana de Endocrinologia y Metabolismo."},{"key":"416_CR181","unstructured":"Sociedade Brasiliera de Diabetes (SBD). Algoritmo para o tratamento do diabetes tipo 2. Atualiza\u00e7\u00e3o 2011. Posicionamento Oficial SBD n\u00b03, 2011."},{"key":"416_CR182","unstructured":"Sociedad Peruana de Endocrinolog\u00eda. Consenso Peruano sobre Prevenci\u00f3n y Tratamiento de Diabetes Mellitus Tipo 2, S\u00edndrome Metab\u00f3lico y Diabetes Gestacional. Congreso Internacional en Prediabetes y S\u00edndrome Metab\u00f3lico 2012. Available at: http:\/\/www.endocrinoperu.org\/pdf\/Consenso%20Peruano%20sobre%20Prevencion%20y%20Tratamiento%20de%20Diabetes%20Mellitus%202%20Sindrome%20Metabolico%20y%20Diabetes%20Gestacional.pdf . Accessed Jan 2015."},{"key":"416_CR183","unstructured":"T\u00fcrkiye Endokrinoloji ve Metabolizma Dernegi. D\u00edabetes Mell\u00edtus Ve Kompl\u00edkasyonlarinin TaniI, Tedav\u00ed Ve \u0130zlem Kilavizu\u20132013. Diabetes Mellitus \u00c7al\u0131\u015fma ve E\u011fitim Grubu 2013. Available at: http:\/\/www.turkendokrin.org\/files\/pdf\/diabetes_klvz2011_web.pdf . Accessed Jan 2015."},{"key":"416_CR184","unstructured":"Eastern Mediterranean Regional office (WHO). Guidelines for the prevention, management and care of diabetes mellitus. EMRO Technical Publications Series 32. Available at: http:\/\/www.emro.who.int\/dsaf\/dsa664.pdf . Accessed Jan 2015."},{"key":"416_CR185","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","volume":"368","author":"J Lindstr\u00f6m","year":"2006","unstructured":"Lindstr\u00f6m J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemi\u00f6 K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673\u20139.","journal-title":"Lancet."},{"key":"416_CR186","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","volume":"348","author":"SU Dombrowski","year":"2014","unstructured":"Dombrowski SU, Knittle K, Avenell A, Ara\u00fajo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014;348:g2646.","journal-title":"BMJ"},{"key":"416_CR187","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577\u201396.","journal-title":"Diabetologia."},{"key":"416_CR188","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14740338.2012.691963","volume":"11","author":"J Kung","year":"2012","unstructured":"Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf. 2012;11:565\u201379.","journal-title":"Expert Opin Drug Saf."},{"key":"416_CR189","unstructured":"National Diabetes education Initiative. Expert Commentary. Silvio E. Inzucchi, MD, on the ORIGIN insulin glargine trial results. Available at: http:\/\/www.ndei.org\/ORIGIN-glargine-study-silvioinzucchi-commentary.aspx . Accessed Jan 2015."},{"key":"416_CR190","first-page":"78","volume":"18","author":"G Arungarinathan","year":"2011","unstructured":"Arungarinathan G, McKay GA, Fisher M. Drugs for diabetes: part 4 acarbose. Br J Cardiol. 2011;18:78\u201381.","journal-title":"Br J Cardiol."},{"key":"416_CR191","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/clp.12.80","volume":"8","author":"KJ Neff","year":"2013","unstructured":"Neff KJ, le Roux CW. Incretins: new targets for the prevention of diabetes and obesity. Clin Lipidol. 2013;8:109\u201321.","journal-title":"Clin Lipidol."},{"key":"416_CR192","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370:794\u20137.","journal-title":"N Engl J Med."},{"key":"416_CR193","unstructured":"Diabetes UK. Coping with your diagnosis: emotional impact and grief. Available at: http:\/\/www.diabetes.co.uk\/emotions\/coping-with-diabetes-diagnosis.html . Accessed May 2015."},{"key":"416_CR194","unstructured":"Diabetes UK. Living with diabetes. Available at: http:\/\/www.diabetes.org.uk\/guide-to-diabetes\/living_with_diabetes . Accessed May 2015."},{"key":"416_CR195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40271-012-0001-0","volume":"6","author":"J Schabert","year":"2013","unstructured":"Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6:1\u201310.","journal-title":"Patient."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0416-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0416-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0416-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:48:48Z","timestamp":1599101328000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0416-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":195,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0416-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]}}}